Ignite Creation Date:
2024-05-06 @ 3:01 AM
Last Modification Date:
2024-10-26 @ 11:27 AM
Study NCT ID:
NCT02186821
Status:
TERMINATED
Last Update Posted:
2021-04-08
First Post:
2014-07-03
Brief Title:
Ceritinib LDK378 for Patients Whose Tumors Have Aberrations in ALK or ROS1 SIGNATURE
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-09-17
Start Date Type:
ACTUAL
Primary Completion Date:
2017-12-13
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-12-13
Completion Date Type:
ACTUAL
First Submit Date:
2014-07-03
First Submit QC Date:
July 8 2014
Study First Post Date:
2014-07-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2021-04-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-03-12
Last Update Post Date:
2021-04-08
Last Update Post Date Type:
ACTUAL